Search results for "Postmenopause"

showing 10 items of 122 documents

[Protein intake in community-dwelling postmenopausal women and its relationship with sarcopenia].

2021

Objectives: the general aging of the population is related to the increase in the prevalence of sarcopenic disease; especially among older women, this pathology is closely related to nutrition and specifically to protein consumption in older adults. The aim of our study was to evaluate the possible relationship between a low protein intake and a higher prevalence of sarcopenic disease, a worse dietary pattern, and lower physical performance in postmenopausal women living in the community. Material and methods: the study was carried out in a total of 164 independent women over 65 years of age, recruited from a municipal social center in Valencia (Benimaclet). The presence of sarcopenic patho…

SarcopeniaLow proteinPopulationMedicine (miscellaneous)DiseaseEnvironmental healthPrevalenceMedicineHumansSarcopenic obesityeducationAgedAged 80 and overeducation.field_of_studyNutrition and DieteticsPostmenopausal womenbusiness.industryMiddle AgedProtein intakeMicronutrientmedicine.diseasePostmenopauseSarcopeniaFemaleDietary ProteinsIndependent LivingbusinessEnergy IntakeNutricion hospitalaria
researchProduct

Therapeutic dosages of raloxifene do not modify myeloperoxidase and F2alpha-isoprostane levels in postmenopausal women.

2005

We investigated the effect of a therapeutic dose of raloxifene on the plasma levels of myeloperoxidase and F2alpha-isoprostanes, two markers of oxidative stress recently described as reliable indicators of coronary heart disease. Contrary to changes described in the literature for estrogens (E), raloxifene did not modify the levels of either myeloproxidase or F2alpha-isoprostanes after 3 or 6 months of treatment.

Selective Estrogen Receptor Modulatorsmedicine.medical_specialtyIsoprostaneNeutrophilsEstrogen receptormedicine.disease_causeAntioxidantschemistry.chemical_compoundTherapeutic indexInternal medicineMedicineHumansRaloxifenePeroxidaseF2-Isoprostanesbiologybusiness.industryObstetrics and GynecologyMiddle AgedAntiestrogenIsoprostanesPostmenopauseOxidative StressEndocrinologyReproductive MedicinechemistryCardiovascular DiseasesMyeloperoxidaseRaloxifene Hydrochloridebiology.proteinFemalebusinessOxidative stressBiomarkersmedicine.drugFertility and sterility
researchProduct

Raloxifene increases the capacity of serum to promote prostacyclin release in human endothelial cells: implication of COX-1 and COX-2.

2004

OBJECTIVE Prostacyclin is a potent vasodilator synthesized by two isoforms of cyclooxygenase in endothelium. The aim of this study was to investigate the effect of serum from postmenopausal women treated with raloxifene on prostacyclin production by human umbilical vein endothelial cells and on cyclooxygenases-1 and -2. DESIGN Serum was collected from 21 women receiving 60 mg/day of raloxifene, at baseline and at 3 and 6 months. Human umbilical vein endothelial cells were exposed to serum for 24 hours, and prostacyclin production was evaluated in supernatants. Selective inhibitors of cyclooxygenases-1 and -2 (SC-560 and NS-398) were used to investigate the relative contribution of each enzy…

Selective Estrogen Receptor Modulatorsmedicine.medical_specialtyUmbilical VeinsEndotheliumCell SurvivalProstacyclinVasodilationUmbilical veinWestern blotInternal medicinemedicineHumansRaloxifeneCyclooxygenase InhibitorsCells CulturedNitrobenzeneschemistry.chemical_classificationSulfonamidesbiologymedicine.diagnostic_testCyclooxygenase 2 Inhibitorsbusiness.industryObstetrics and GynecologyEndothelial CellsMembrane ProteinsMiddle AgedEpoprostenolImmunohistochemistryIsoenzymesPostmenopausemedicine.anatomical_structureEnzymeEndocrinologychemistryCyclooxygenase 2Prostaglandin-Endoperoxide SynthasesRaloxifene Hydrochloridecardiovascular systembiology.proteinCyclooxygenase 1PyrazolesFemaleCyclooxygenasebusinessmedicine.drugMenopause (New York, N.Y.)
researchProduct

Circulating miR-21, miR-146a and Fas ligand respond to postmenopausal estrogen-based hormone replacement therapy--a study with monozygotic twin pairs.

2014

Biological aging is associated with physiological deteriorations and its’ remodeling, which are partly due to changes in the hormonal profile. MicroRNAs are known to post-transcriptionally regulate various cellular processes associated with cell senescence; differentiation, replication and apoptosis. Measured from the serum, microRNAs have the potential to serve as noninvasive markers for diagnostics/prognostics and therapeutic targets. We analysed the association of estrogen-based hormone replacement therapy (HRT) with selected microRNAs and inflammation markers from the serum, leukocytes and muscle tissue biopsy samples obtained from 54-62 year-old postmenopausal monozygotic twins (n=11 p…

SenescenceAdultmedicine.medical_specialtyAgingFas Ligand Proteinmedicine.drug_classmedicine.medical_treatmentMonozygotic twinInflammationApoptosisBiologyta3111Fas ligand“Inflamm-aging”Internal medicinemicroRNAmedicineestrogenHumansmicrornasMuscle SkeletalHormone therapyCellular SenescenceInflammationmicroRNAEstrogen Replacement TherapyapoptosisHormone replacement therapy (menopause)ta3141Cell DifferentiationEstrogenstwinsTwins MonozygoticMiddle AgedPostmenopauseAgeinghormone replacement therapyMicroRNAsEndocrinologyEstrogenFemalemedicine.symptomBiomarkersDevelopmental BiologyHormoneMechanisms of ageing and development
researchProduct

Efficacy of Low-Dose Paroxetine for the Treatment of Hot Flushes in Surgical and Physiological Postmenopausal Women: Systematic Review and Meta-Analy…

2019

Background and Objectives: Hot flushes and sleep disturbances are the most common vasomotor symptoms (VMS) reported by postmenopausal women. Hormonal treatment is to date referred to as the gold standard approach but not suitable for all the patients. Alternative treatments are needed in case of a contraindication to menopausal hormone therapy (MHT), adverse side effects, and poor compliance. Paroxetine salt is the only nonhormonal medication approved by the US Food and Drug Administration for the management of VMS. Nonetheless, few trials with low consensus are available about this topic. In this review, we aimed to evaluate the efficacy of low-dose paroxetine therapy in the treatment of v…

Sleep Wake Disordersmedicine.medical_specialtyMedicine (General)Ovariectomyvasomotor symptomsefficacymenopauseReviewPlacebosleep disturbanceslaw.inventionR5-920Randomized controlled triallawInternal medicinemedicineHumanshot flusheAdverse effectContraindicationRandomized Controlled Trials as TopicVasomotorbusiness.industryGeneral Medicinemedicine.diseasesleep disturbanceParoxetineMenopausePostmenopauseParoxetineMeta-analysisefficacy; hot flushes; menopause; paroxetine; sleep disturbances; vasomotor symptomsHot FlashesFemalehot flushesbusinessSelective Serotonin Reuptake Inhibitorsmedicine.drugMedicina
researchProduct

Management of urinary incontinence in postmenopausal women: An EMAS clinical guide.

2020

INTRODUCTION: The prevalence of urinary incontinence and of other lower urinary tract symptoms increases after the menopause and affects between 38 % and 55 % of women aged over 60 years. While urinary incontinence has a profound impact on quality of life, few affected women seek care. AIM: The aim of this clinical guide is to provide an evidence-based approach to the management of urinary incontinence in postmenopausal women. MATERIALS AND METHODS: Literature review and consensus of expert opinion. SUMMARY RECOMMENDATIONS: Healthcare professionals should consider urinary incontinence a clinical priority and develop appropriate diagnostic skills. They should be able to identify and manage a…

Stress incontinencemedicine.medical_specialtyAgingUrinary incontinenceUrinary incontinenceGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicineQuality of lifeLower urinary tract symptomsmedicineHumans030212 general & internal medicineMidurethral SlingsAging; Estrogens; Menopause; Midurethral slings; Urinary incontinence030219 obstetrics & reproductive medicinePostmenopausal womenbusiness.industryObstetrics and GynecologyEstrogensmedicine.diseasePostmenopauseMenopauseUrinary IncontinenceSacral nerve stimulationPhysical therapyFemaleMidurethral slingsmedicine.symptomMenopausebusiness
researchProduct

Phytoestrogens increase the capacity of serum to stimulate prostacyclin release in human endothelial cells

2003

Both the estrogen receptor (ER) alpha and beta isoforms are expressed in the endothelium. The ER beta has been assigned a crucial role in normal vascular wall function. Prostacyclin has been ascribed a beneficial effect on vessel wall physiology. Isoflavones bind with higher affinity to ER beta. We investigated the hypothesis that their administration to postmenopausal women can promote endothelial prostacyclin production.Twenty-five healthy postmenopausal women with mild climacteric symptoms received capsules containing 55 mg/day isoflavones derived from soy and red clover for 6 months. Cultured human umbilical vein endothelial cells (HUVECs) were exposed for 24 h to serum collected before…

Umbilical Veinsmedicine.medical_specialtyTime FactorsEndotheliumAdministration OralAlpha (ethology)Estrogen receptorPhytoestrogensProstacyclinDrug Administration ScheduleUmbilical veinchemistry.chemical_compoundInternal medicinemedicineHumansEstrogens Non-SteroidalEstrogen receptor betaPlant Extractsbusiness.industryObstetrics and GynecologyGeneral MedicineMiddle AgedIsoflavonesBlood Physiological PhenomenaEpoprostenolIsoflavonesPostmenopauseEndocrinologymedicine.anatomical_structurechemistryFemaleTrifoliumPhytoestrogensEndothelium VascularPlant PreparationsSoybeansbusinessPlatelet Aggregation Inhibitorsmedicine.drugActa Obstetricia et Gynecologica Scandinavica
researchProduct

Collagen overglycosylation: a biochemical feature that may contribute to bone quality.

2005

Skeletal ability to resist mechanical stress is determined by bone amount and quality, which relies on macro- and micro-architecture, turnover, bone matrix, and mineralisation; the role of collagen has not been clearly elucidated. Numerous post-translational steps are involved in collagen type I biosynthesis, including residue hydroxylation and glycosylation catalysed by enzymes that work until the protein folds forming the triple helix; therefore, folding rate regulates these processes. Overglycosylated hydroxylysines are poor substrates for epsilon-amino group deamination which initiates cross-link formation. Three clinical conditions associated with fractures may relate collagen overglyc…

chemistry.chemical_classificationGlycosylationGlycosylationOsteoporosisBiophysicsDeaminationCell BiologyOsteogenesis Imperfectamedicine.diseaseBiochemistryBone and BonesHydroxylationPostmenopausechemistry.chemical_compoundEnzymeBiosynthesischemistryBiochemistryDiabetes Mellitus Type 2Osteogenesis imperfectamedicineHumansCollagenMolecular BiologyTriple helixBiochemical and biophysical research communications
researchProduct

Evaluation of the risk factors of asymptomatic vertebral fractures in postmenopausal women with osteopenia at the femoral neck

2016

To identify risk factors of asymptomatic vertebral fracture (aVF) in postmenopausal women with osteopenia at the femoral neck and to evaluate the association between the number of aVFs and the risk of major and hip osteoporotic fracture calculated with the FRAX(®) algorithm.Epidemiological case-series study with data collected transversally.728 postmenopausal women with osteopenia were included: 284 (39.0%) had aVF, of whom 200 (70.4%) had prior fragility fractures (FF). The likelihood of having an osteoporotic fracture in the next 10 years increased significantly with the number of aVF. The percentage of women with height loss, which was assessed as the difference between the greatest heig…

congenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyFRAXBone density030209 endocrinology & metabolismRisk AssessmentAsymptomaticGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicineBone DensityRisk FactorsEpidemiologymedicineHumanscardiovascular diseases030212 general & internal medicineAgedRetrospective StudiesFemoral neckFemur NeckHip Fracturesbusiness.industryObstetrics and GynecologyRetrospective cohort studyMiddle Agedmedicine.diseaseSurgeryPostmenopauseOsteopeniaBone Diseases Metabolicmedicine.anatomical_structureSpainMultivariate AnalysisSpinal FracturesFemalemedicine.symptombusinessRisk assessmentAlgorithmsOsteoporotic Fractures
researchProduct

Serum inhibin A, inhibin B, pro-alphaC, and activin A levels in women with idiopathic premature ovarian failure.

2003

Serum inhibin A, inhibin B, pro-alphaC, and activin A levels in 30 women with idiopathic premature ovarian failure (POF), 30 postmenopausal women, and 30 age-matched fertile women were determined. Women with POF showed low levels of inhibin A and inhibin B, but not of activin A, whereas the levels of pro-alphaC were significantly higher than in postmenopausal women. Thus, the circulating level of pro-alphaC could be a marker for assessing residual ovarian function in women with POF.

endocrine systemInhibin amedicine.medical_specialtyendocrine system diseasesPrimary Ovarian InsufficiencyAndrologyOvarian functionInternal medicineMedicineHumansInhibinsProtein Precursorsreproductive and urinary physiologyInhibin bPostmenopausal womenbusiness.industryObstetrics and Gynecologyfemale genital diseases and pregnancy complicationsActivin aPostmenopauseIdiopathic premature ovarian failureEndocrinologyReproductive MedicineFemalebusinesshormones hormone substitutes and hormone antagonistsFertility and sterility
researchProduct